Explore the latest deal across all financial deal types and actionable insights by Theme and Sector to support your business activities and workflows.

South Korea: Five largest Private Equity/Venture Financing deals by value in the Pharmaceuticals sector (LTM June 2022)

  • A total of 63 Private Equity/Venture Financing deals (pending and completed) were announced in the Pharmaceuticals of South Korea, in the last twelve months resulting in a total deal value of over $2,601.1 million. In the LTM period, August 2021 turned out to be the most prolific in terms of deal size, with a total deal value of $1,591.1 million, resulting in an average deal value of $176.8 million during that month. On the other hand, the month of June 2021 was the most prolific in terms of deal volume, recording a total of 10 deals, resulting in an average deal value of $18.7 million during that month.

  • Of the 63 deals, the deal secured between CBC Group and Hugel Inc, was the largest Private Equity/Venture Financing deal in the South Korea Pharmaceuticals sector, which was valued at $1,500.0 million and was completed on August 27, 2021. The second-largest deal was between Atinum Investment Co Ltd; Daily Partners Co., Ltd.; KB Investment Co Ltd; Korea Investment Partners Co Ltd; Quad Investment Management Corp; SG Private Equity and LegoChem Biosciences Inc, while the third-largest deal was between Atinum Investment Co Ltd; Imm Investment Corp; InterVest Co., Ltd.; KB Investment Co Ltd; KDB Investment Co Ltd and Orum Therapeutics Inc. The Atinum Investment Co Ltd; Daily Partners Co., Ltd.; KB Investment Co Ltd; Korea Investment Partners Co Ltd; Quad Investment Management Corp; SG Private Equity-LegoChem Biosciences Inc deal and the Atinum Investment Co Ltd; Imm Investment Corp; InterVest Co., Ltd.; KB Investment Co Ltd; KDB Investment Co Ltd-Orum Therapeutics Inc deal were valued at $140.8 million and $54.0 million, respectively. The fourth-largest deal was between DS Asset Management; Korea Investment & Securities Co Ltd; Kudos Ventures; Praxis Capital Partners-D&D Pharmatech Co Ltd valued at $51.0 million, whereas the deal between Chong Kun Dang Holdings Corp; Daily Partners Co., Ltd.; E&Venture Partners; Imm Investment Corp; LSK Investment Inc; NHN Investment Co.,Ltd.; SBI Investment Korea Co Ltd; Smilegate Investment Inc; Stick Ventures; Withwin Investment Association 50-Biorchestra Co Ltd valued at $45.4 million was the fifth-largest deal.

  • Cumulatively, the top five deals amounted to $1,791.2 million and accounted for nearly 68.86% of the total deals (by value) announced during the last twelve months.

South Korea: Five largest Private Equity/Venture Financing deals by value in the Pharmaceuticals sector (LTM June 2022)

Published: June 2022
Source: GlobalData

Explore the latest deal across all financial deal types and actionable insights by Theme and Sector to support your business activities and workflows. Explore the latest deal across all financial deal types and actionable insights by Theme and Sector to support your business activities and workflows. Visit Report Store

Related Companies

Johnson & Johnson

United States of America

HCA Healthcare Inc

United States of America

Merck & Co Inc

United States of America

Pfizer Inc

United States of America

AbbVie Inc

United States of America

Bayer AG

Germany

Sanofi

France

Novartis AG

Switzerland

Still looking?

Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward